People with HER2-positive gastric cancer should not take proton pump inhibitors for heartburn while they are undergoing treatment, recent studies have found.
Tumor-associated macrophages represent an exciting new target in the development of treatments for gastric cancer.
MacroGenics received orphan drug designation from the FDA for its investigational gastric cancer drug margetuximab.
A recent trial of a combination of Stivarga and Opdivo showed better activity than either drug alone in patients with gastric cancer.
The FDA approved Deciphera Pharmaceuticals’ Quinlock (ripretinib) for the treatment of advanced gastrointestinal stromal tumors.
An early trial of AstraZeneca’s MET inhibitor savolitinib in gastric cancer revealed mutations that confer drug resistance.